T-Zell-Rezeptorvariante gegen Mkras 7-16 G12D

Details

Veröffentlichungs-Nr.

EP4737476

Anmeldetag

12. September 2024

Veröffentlichung

6. Mai 2026

Rechtsraum

EP

IPC

(PERRET RACHEL et al.)(US HEALTH et al.)

Abstract

The present invention relates to a novel TCR characterized by its CDR3 sequences of the α chain variable region and/or the β chain variable region. The present invention relates to a TCR polypeptide complex and/or a combination comprising a novel TCR characterized by its CDR3 sequences of the α chain variable region and/or the β chain variable region. The present invention further relates to a nucleic acid, a vector as well as a host cell comprising said nucleic acid or said vector. The present invention relates to a method for obtaining said TCR and said chimeric co-stimulatory receptor and to a pharmaceutical or diagnostic composition comprising the abovementioned. The present invention further relates to the abovementioned for use as a medicament or for use in a method of diagnosing, detecting, preventing, and/or treating cancer. Furthermore, the present invention relates to a method of detecting the presence of a cancer in a subject in vitro, by applying within said method the abovementioned, and the use of the abovementioned for generating modified lymphocytes and a kit.

Anmelder

Firma

Medigene Immunotherapies GmbH

Land

🇩🇪 Deutschland